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Editorial on the Research Topic
Developing Successful Neuroprotective Treatments for TBI: Translational Approaches, Novel
Directions, Opportunities and Challenges
Traumatic brain injury (TBI) constitutes a critical health problem. More than 50 million new cases
occur worldwide each year, accounting for upwards of a million deaths (roughly 2,700 deaths
per day) and a global financial burden of $US400 billion (1, 2). Overall, TBI-related disability is
increasing globally, negatively affecting families and society, as well as health-care systems and
economies (2). Among survivors, nearly half of those with moderate or severe TBI require years
of intensive therapy and face substantial functional impairment and reduced life expectancy (3);
however, also mild TBIs and concussions can lead to persistent adverse outcomes.
Despite thousands of preclinical studies in laboratory animals and hundreds of
randomized controlled clinical trials (RCTs) testing neuroprotection approaches with different
pathophysiological targets (4, 5), to date, no intervention has demonstrated to be unequivocal
effective and improve the long-term functional outcome following TBI (1, 6).
This book incorporates reviews and research articles from leaders in the field describing
promising therapeutic avenues, which span the spectra of TBI severity and have undergone
experimental and clinical investigation. What emerges is a panoramic view of a field actively
exploring alternative strategies and novel directions, such as preclinical-drug screening multimodel
multispecies consortia (Kochanek et al.) (7, 8), capable to tackle the challenge of heterogeneity
in TBI.
Recognizing the critical neuronal loss and wide variability existing in pathophysiologic
mechanisms triggered by TBI, the current focus is on the regenerative potential and pleiotropic
neuroprotective properties of stem cell therapy for TBI (9, 10). Accordingly, diverse authors
have provided perspectives with respect to the application of mesenchymal stromal cells (MSCs)
(Carbonara et al.) and the anti-inflammatory role of neural stem cell transplantation (Kassi et al.),
and also generated new compelling data (Nasser et al.).
Sophisticated experiments reinterpreting previous unsuccessful therapeutic interventions (11,
12), including erythropoietin (Robinson et al.), hypothermia (Szczygielski et al.), and selective brain
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cooling (Leung et al.) have also been conducted providing
authors with the opportunity to identify potential reasons for
clinical failure. In this analysis, a complex array of factors,
comprising a lack of precise diagnose and endophenotype
characterization, inadequate measures of outcomes, and tools to
inform tailored and individualized treatment emerges as main
barriers to advance clinical care in TBI (13). Complementing this
conceptual framework, a strong emphasis has also been placed by
several contributors on the need for a mechanistic approach to
guide drug development. This strategy can better inform target
selection and streamline the hard translational decision process.
As a consequence, investigations on mitochondrial dysfunction
(Pandya et al.), microglial activation (Madathil et al.), cerebral
microcirculation impairment (Bellapart et al.), and gut dysbiosis
(Rice et al.) following TBI are presented, highlighting their
directly involvement in disease pathogenesis and outcome, and
role as therapeutic target candidates.
Finally, the volume includes experimental and human studies
which add further evidence for the use of neuroimaging (Bajaj
et al.) and biofluid markers (Bhatti et al. and DeDominicis
et al.) as surrogate endpoints of clinical benefit and treatment
response after therapeutic intervention in TBI, supporting
their incorporation in future clinical trials (14). Imaging and
biofluid markers can, in fact, be instrumental in identifying and
characterizing pathophysiologic mechanisms leading to more
accurate and finer-grained disease classification which, in turn,
may be used to enrich or stratify patient groups, to demonstrate
target engagement, and/or as proof of treatment efficacy (14–
16). These factors can play a transformative role in designing
effective clinical trials, increasing treatment effectiveness as well
as reducing healthcare costs (16–18).
Overall, this volume is intended to provide novel perspectives
and insights into the critical research area of TBI treatment, foster
knowledge and innovation in the arena of drug development, and
stimulates new frameworks and testable hypotheses that can help
inform and refine the next generation of TBI clinical trials.
We thank our colleagues for devoting their time, efforts, and
clinical and scientific experience. This book would not have been
possible without their important contributions. We also thank
the editorial team for their dedicated support and assistance.
Last, and most important, we are indebted to all patients
with TBI and their families for their invaluable contributions.
They represent our greatest source of inspiration and all our
endeavors are directed toward improving their outcome and
quality of life.
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